字号·· | 护眼
彭博社

FDA计划在2027年3月前完成堕胎药安全报告FDA Plans to Finish Safety Report on Abortion Pill by March 2027

点「原文对照」整页切到原文,或双击某段只看那段的原文。

米非司酮片剂包装Packages of Mifepristone tablets

美国卫生官员预计,他们将在明年3月前完成一份关于堕胎药物米非司酮安全性的报告。美国食品药品监督管理局(FDA)网站周二发布的最新消息显示了这一时间表。

US health officials anticipate they will complete a report on the safety of the abortion drug mifepristone by next March, according to an update on the Food and Drug Administration’s website Tuesday.

FDA正在利用联邦和私人医疗保险计划的理赔数据,将米非司酮与另一种名为米索前列醇的药物联合使用的安全性与手术堕胎进行比较。该机构预计下个月将获得分析结果。

The FDA is using claims data from federal and private health insurance plans to compare the safety of mifepristone use, in combination with another drug called misoprostol, to surgical abortion. The agency expects to obtain the results from its analysis next month.

最新消息称:“届时FDA将需要审查结果并起草报告,该机构目前预计这一过程最迟在2027年3月前完成。”该机构没有立即回应置评请求。

“FDA will then need to review the results and draft its report, a process that the agency currently expects to complete by not later than March 2027,” the update said. The agency didn’t immediately respond to a request for comment.

一些共和党议员一直敦促FDA进行堕胎药安全性研究——尽管许多主要医疗组织长期以来一直认为该药物是安全的。他们的目标是推翻拜登时期的政策,这些政策使人们无需亲自就诊即可获得堕胎药。

Some Republican lawmakers have pressed the FDA to conduct an abortion pill safety study — despite many leading medical organizations having long deemed the drug safe. Their goal is to roll back Biden-era policies that made the abortion pill available without an in-person doctor’s visit.

FDA在其处方信息中引用的研究显示,严重副作用的发生率低于0.5%。据美国公民自由联盟称,该药物用于美国近三分之二的堕胎以及流产处理。该组织估计,自FDA于2000年首次批准该药物以来,约有750万美国人服用过该药。

Studies the FDA cites in its prescribing information puts the rate of serious side effects at less than 0.5%. The drug is used in nearly two-thirds of US abortions and for miscarriage management, according to the American Civil Liberties Union, which estimates that roughly 7.5 million Americans have taken the drug since the FDA first approved it in 2000.

被提名为FDA局长的海蒂·奥弗顿预计周三将在参议院面临一道关卡,届时卫生、教育、劳工和养老金委员会将投票决定是否建议将她提交全院表决。

Heidi Overton, the nominee to become FDA commissioner, is expected to face a Senate hurdle on Wednesday when the Health, Education, Labor and Pensions committee will vote on whether to recommend her to a full floor vote.

在包括委员会主席、来自路易斯安那州的比尔·卡西迪在内的关键共和党人提出批评后,她的提名并未面临一条明确的通路。来自密苏里州的共和党参议员乔什·霍利也批评她延续了允许人们通过邮件订购米非司酮的政策。

Her nomination doesn’t face a clear path following criticisms from key Republicans, including committee chairman Bill Cassidy from Louisiana. Republican Senator Josh Hawley from Missouri has also criticized her for continuing policies that have allowed people to order mifepristone through mail.

奥弗顿此前曾在美国优先研究所担任首席政策官,她在那里撰写了一份政策简报,称药物流产“危险”。如果委员会批准奥弗顿的提名,她将成为数月来首位常任专员。此前该机构经历了领导层动荡,时任专员马蒂·马卡里于5月离职。

Overton previously worked as a chief policy officer at the America First Institute, where she wrote a policy brief calling chemical abortions “dangerous.”If the committee approves Overton’s nomination, she would be the first permanent commissioner in months following leadership turmoil when then-Commissioner Marty Makary left his post in May.

阅读媒体原文 ↗